Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Urinary Incontinence

ClinicalTrials.gov lists 1,590 trials for Urinary Incontinence or a narrower condition beneath it. Coloplast A/S has the most among industry and government lead sponsors, with 20.

MeSH D014549 Urogenital Diseases C12 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 31 Phase 1/2 Phase 1/2 22 Phase 2 Phase 2 67 Phase 2/3 Phase 2/3 18 Phase 3 Phase 3 115 Phase 4 Phase 4 88 Not applicable Not applicable 914 Observational Observational 333 Phase 1 Phase 1 31 Phase 1/2 Phase 1/2 22 Phase 2 Phase 2 67 Phase 2/3 Phase 2/3 18 Phase 3 Phase 3 115 Phase 4 Phase 4 88 Not applicable Not applicable 914 Observational Observational 333

Trials per phase (log scale)

1 more section with rows

933 of the 1,590 trials are tagged with Urinary Incontinence itself; the rest are tagged with a narrower condition beneath it.

Get the Urinary Incontinence report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Urinary Incontinence trials start? (32)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 118

1993: 1 trials (Observational 1) 1995: 1 trials (Phase 3 1) 1996: 2 trials (Phase 3 2) 1997: 2 trials (Observational 1, Phase 3 1) 1999: 1 trials (Phase 2 1) 2000: 2 trials (Phase 3 2) 2001: 11 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 6, Phase 2 1) 2002: 9 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1 1) 2003: 11 trials (Observational 1, Not applicable 3, Phase 3 6, Phase 1/2 1) 2004: 27 trials (Observational 5, Not applicable 8, Phase 4 5, Phase 3 5, Phase 2 4) 2005: 32 trials (Observational 1, Not applicable 14, Phase 4 6, Phase 3 5, Phase 2 5, Phase 1/2 1) 2006: 34 trials (Observational 7, Not applicable 9, Phase 4 7, Phase 3 5, Phase 2 5, Phase 1/2 1) 2007: 32 trials (Observational 6, Not applicable 10, Phase 4 6, Phase 3 3, Phase 2 6, Phase 1 1) 2008: 42 trials (Observational 8, Not applicable 12, Phase 4 9, Phase 3 7, Phase 2/3 3, Phase 2 1, Phase 1 2) 2009: 40 trials (Observational 10, Not applicable 13, Phase 4 5, Phase 3 5, Phase 2 1, Phase 1/2 2, Phase 1 4) 2010: 36 trials (Observational 8, Not applicable 15, Phase 4 3, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 1) 2011: 33 trials (Observational 8, Not applicable 12, Phase 4 3, Phase 3 4, Phase 2 2, Phase 1/2 1, Phase 1 3) 2012: 48 trials (Observational 14, Not applicable 23, Phase 4 3, Phase 3 6, Phase 2/3 1, Phase 1/2 1) 2013: 55 trials (Observational 10, Not applicable 26, Phase 3 10, Phase 2/3 1, Phase 2 2, Phase 1/2 5, Phase 1 1) 2014: 62 trials (Observational 19, Not applicable 30, Phase 4 4, Phase 3 5, Phase 2/3 2, Phase 1 2) 2015: 65 trials (Observational 9, Not applicable 45, Phase 4 2, Phase 3 5, Phase 2 1, Phase 1/2 2, Phase 1 1) 2016: 71 trials (Other 1, Observational 16, Not applicable 35, Phase 4 4, Phase 3 7, Phase 2/3 2, Phase 2 4, Phase 1/2 1, Phase 1 1) 2017: 78 trials (Observational 19, Not applicable 50, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 4) 2018: 88 trials (Observational 18, Not applicable 55, Phase 4 4, Phase 3 5, Phase 2/3 1, Phase 2 3, Phase 1/2 2) 2019: 103 trials (Observational 23, Not applicable 65, Phase 4 6, Phase 3 2, Phase 2/3 1, Phase 2 4, Phase 1 2) 2020: 85 trials (Other 1, Observational 17, Not applicable 56, Phase 4 2, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2021: 97 trials (Observational 23, Not applicable 65, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1 3) 2022: 112 trials (Observational 23, Not applicable 78, Phase 4 4, Phase 3 3, Phase 2 2, Phase 1 2) 2023: 95 trials (Observational 14, Not applicable 74, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2024: 106 trials (Observational 25, Not applicable 72, Phase 4 3, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2025: 118 trials (Observational 22, Not applicable 85, Phase 4 4, Phase 3 3, Phase 2/3 1, Phase 2 2, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 83
2025 118
2024 106
2023 95
2022 112
2021 97
2020 85
2019 103
2018 88
2017 78

Forecast of the full-year count, planned starts included, not rows of this table: about 100 trials starting in 2026 and about 110 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 35 months from start to primary completion across 126 trials still running at the 2026-10-09 snapshot; registered median of 17 months across 1,002 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Urinary Incontinence trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 31
Phase 1/2 22
Phase 2 67
Phase 2/3 18
Phase 3 115
Phase 4 88
Not applicable 914
Observational 333
Unknown 2

How many Urinary Incontinence trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 76
Recruiting 145
Enrolling by invitation 14
Active, not recruiting 59
Completed 915

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Urinary Incontinence trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Coloplast A/S 20
Eli Lilly and Company 17
Allergan 14
Astellas Pharma Inc 13
NICHD Pelvic Floor Disorders Network 11

Which drugs are being tested for Urinary Incontinence? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Tolterodine 20
Duloxetine 18
Iltamiocel 6
Tamsulosin 4
GTx 024 4

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Solifenacin PO 32
mirabegron OCAS 27
type A botulinum toxin 26
[PRP] platelet rich plasma 10
Control (placebo) group 8

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Urinary Incontinence trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 63 27
Osteoarthritis 60 15
Genitourinary 47 1
Urinary tract infection 38 15
Atrial fibrillation 31 16

Which publications cover Urinary Incontinence? (1,658)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages